November 2026—Roche received FDA 510(k) clearance for its Cobas BV/CV assay. It uses real-time polymerase chain reaction technology to identify the bacteria and yeast responsible for bacterial vaginosis and Candida vaginitis from symptomatic patients.
The test detects DNA targets for organisms associated with BV, including Gardnerella vaginalis, Atopobium vaginae, and Lactobacillus spp. It also detects Candida species associated with CV, including C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, and C. dubliniensis. The sample is collected using a clinician-collected or clinician-instructed, self-collected vaginal swab in Cobas PCR media in a health care setting. It runs on Cobas 6800/8800 systems.
In a separate announcement, Roche introduced its Cobas HDV test for use in the detection and quantification of hepatitis D virus RNA. The assay runs on the Cobas 5800, 6800, and 8800 systems. It is available in countries that accept the CE mark.
Roche, 800-428-5074